Rydapt Approved for Adults With Acute Myeloid Leukemia

FRIDAY, April 28, 2017 — Rydapt (midostaurin) has been approved by the U.S. Food and Drug Administration, in combination with chemotherapy, to treat adults with acute myeloid leukemia (AML) who have a specific genetic mutation dubbed FLT3.
AML, a…
Source: Topamax